443 related articles for article (PubMed ID: 34319126)
1. Rapid and Flexible Platform To Assess Anti-SARS-CoV-2 Antibody Neutralization and Spike Protein-Specific Antivirals.
Stelitano D; Weisberg SP; Goldklang MP; Zhu Y; Bovier FT; Kalantarov GF; Greco G; Decimo D; Franci G; Cennamo M; Portella G; Galdiero M; Mathieu C; Horvat B; Trakht IN; Moscona A; Whitt MA; Porotto M
mSphere; 2021 Aug; 6(4):e0057121. PubMed ID: 34319126
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein.
Tani H; Kimura M; Tan L; Yoshida Y; Ozawa T; Kishi H; Fukushi S; Saijo M; Sano K; Suzuki T; Kawasuji H; Ueno A; Miyajima Y; Fukui Y; Sakamaki I; Yamamoto Y; Morinaga Y
Virol J; 2021 Jan; 18(1):16. PubMed ID: 33435994
[TBL] [Abstract][Full Text] [Related]
3. An Assessment of Serological Assays for SARS-CoV-2 as Surrogates for Authentic Virus Neutralization.
Wohlgemuth N; Whitt K; Cherry S; Kirkpatrick Roubidoux E; Lin CY; Allison KJ; Gowen A; Freiden P; Allen EK; ; Gaur AH; Estepp JH; Tang L; Mori T; Hijano DR; Hakim H; McGargill MA; Krammer F; Whitt MA; Wolf J; Thomas PG; Schultz-Cherry S
Microbiol Spectr; 2021 Oct; 9(2):e0105921. PubMed ID: 34704832
[TBL] [Abstract][Full Text] [Related]
4. Neutralization assay with SARS-CoV-1 and SARS-CoV-2 spike pseudotyped murine leukemia virions.
Zheng Y; Larragoite ET; Williams ESCP; Lama J; Cisneros I; Delgado JC; Slev P; Rychert J; Innis EA; Coiras M; Rondina MT; Spivak AM; Planelles V
Virol J; 2021 Jan; 18(1):1. PubMed ID: 33397387
[TBL] [Abstract][Full Text] [Related]
5. Neutralizing antibody response elicited by SARS-CoV-2 receptor-binding domain.
Huang PH; Tsai HH; Liao BH; Lin YL; Jan JT; Tao MH; Chou YC; Hu CJ; Chen HW
Hum Vaccin Immunother; 2021 Mar; 17(3):654-655. PubMed ID: 32991231
[TBL] [Abstract][Full Text] [Related]
6. Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera.
Oguntuyo KY; Stevens CS; Hung CT; Ikegame S; Acklin JA; Kowdle SS; Carmichael JC; Chiu HP; Azarm KD; Haas GD; Amanat F; Klingler J; Baine I; Arinsburg S; Bandres JC; Siddiquey MNA; Schilke RM; Woolard MD; Zhang H; ; Duty AJ; Kraus TA; Moran TM; Tortorella D; Lim JK; Gamarnik AV; Hioe CE; Zolla-Pazner S; Ivanov SS; Kamil JP; Krammer F; Lee B
mBio; 2021 Feb; 12(1):. PubMed ID: 33593976
[TBL] [Abstract][Full Text] [Related]
7. Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection.
Sulbaran G; Maisonnasse P; Amen A; Effantin G; Guilligay D; Dereuddre-Bosquet N; Burger JA; Poniman M; Grobben M; Buisson M; Dergan Dylon S; Naninck T; Lemaître J; Gros W; Gallouët AS; Marlin R; Bouillier C; Contreras V; Relouzat F; Fenel D; Thepaut M; Bally I; Thielens N; Fieschi F; Schoehn G; van der Werf S; van Gils MJ; Sanders RW; Poignard P; Le Grand R; Weissenhorn W
Cell Rep Med; 2022 Feb; 3(2):100528. PubMed ID: 35233549
[TBL] [Abstract][Full Text] [Related]
8. Robust Neutralizing Antibody Levels Detected after Either SARS-CoV-2 Vaccination or One Year after Infection.
Glöckner S; Hornung F; Baier M; Weis S; Pletz MW; Deinhardt-Emmer S; Löffler B; The CoNAN Study Group
Viruses; 2021 Oct; 13(10):. PubMed ID: 34696428
[TBL] [Abstract][Full Text] [Related]
9. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
[TBL] [Abstract][Full Text] [Related]
10. Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8
Ishii H; Nomura T; Yamamoto H; Nishizawa M; Thu Hau TT; Harada S; Seki S; Nakamura-Hoshi M; Okazaki M; Daigen S; Kawana-Tachikawa A; Nagata N; Iwata-Yoshikawa N; Shiwa N; Suzuki T; Park ES; Ken M; Onodera T; Takahashi Y; Kusano K; Shimazaki R; Suzaki Y; Ami Y; Matano T
Cell Rep Med; 2022 Feb; 3(2):100520. PubMed ID: 35233545
[TBL] [Abstract][Full Text] [Related]
11. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
[TBL] [Abstract][Full Text] [Related]
12. Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.
Rosati M; Terpos E; Ntanasis-Stathopoulos I; Agarwal M; Bear J; Burns R; Hu X; Korompoki E; Donohue D; Venzon DJ; Dimopoulos MA; Pavlakis GN; Felber BK
Front Immunol; 2021; 12():793953. PubMed ID: 34899762
[TBL] [Abstract][Full Text] [Related]
13. Scalable, Micro-Neutralization Assay for Assessment of SARS-CoV-2 (COVID-19) Virus-Neutralizing Antibodies in Human Clinical Samples.
Bennett RS; Postnikova EN; Liang J; Gross R; Mazur S; Dixit S; Kocher G; Yu S; Georgia-Clark S; Gerhardt D; Cai Y; Marron L; Lukin VV; Holbrook MR
Viruses; 2021 May; 13(5):. PubMed ID: 34065987
[TBL] [Abstract][Full Text] [Related]
14. A real-time and high-throughput neutralization test based on SARS-CoV-2 pseudovirus containing monomeric infrared fluorescent protein as reporter.
Tsai WY; Ching LL; Hsieh SC; Melish ME; Nerurkar VR; Wang WK
Emerg Microbes Infect; 2021 Dec; 10(1):894-904. PubMed ID: 33929934
[TBL] [Abstract][Full Text] [Related]
15. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
16. Neutralizing Antibody Responses to SARS-CoV-2 in Recovered COVID-19 Patients Are Variable and Correlate With Disease Severity and Receptor-Binding Domain Recognition.
Maciola AK; La Raja M; Pacenti M; Salata C; De Silvestro G; Rosato A; Pasqual G
Front Immunol; 2022; 13():830710. PubMed ID: 35173741
[TBL] [Abstract][Full Text] [Related]
17. Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2.
Park JG; Oladunni FS; Chiem K; Ye C; Pipenbrink M; Moran T; Walter MR; Kobie J; Martinez-Sobrido L
J Virol Methods; 2021 Jan; 287():113995. PubMed ID: 33068703
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of serological anti-SARS-CoV-2 chemiluminescent immunoassays correlated to live virus neutralization test, for the detection of anti-RBD antibodies as a relevant alternative in COVID-19 large-scale neutralizing activity monitoring.
Cristiano A; Pieri M; Sarubbi S; Pelagalli M; Calugi G; Tomassetti F; Bernardini S; Nuccetelli M
Clin Immunol; 2022 Jan; 234():108918. PubMed ID: 34971839
[TBL] [Abstract][Full Text] [Related]
19. A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo.
Hanke L; Das H; Sheward DJ; Perez Vidakovics L; Urgard E; Moliner-Morro A; Kim C; Karl V; Pankow A; Smith NL; Porebski B; Fernandez-Capetillo O; Sezgin E; Pedersen GK; Coquet JM; Hällberg BM; Murrell B; McInerney GM
Nat Commun; 2022 Jan; 13(1):155. PubMed ID: 35013189
[TBL] [Abstract][Full Text] [Related]
20. Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients.
Ruetalo N; Businger R; Althaus K; Fink S; Ruoff F; Pogoda M; Iftner A; Ganzenmüller T; Hamprecht K; Flehmig B; Bakchoul T; Templin MF; Schindler M
mSphere; 2021 Feb; 6(1):. PubMed ID: 33627511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
